Adjuvant Everolimus Falls Short in High-Risk Kidney Cancer
(MedPage Today) -- Adjuvant everolimus (Afinitor) failed to significantly improve recurrence-free survival (RFS) in patients with renal cell carcinoma (RCC) who were at high risk for recurrence after nephrectomy, according to results from a randomized... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 31, 2023 Category: Hematology Source Type: news
Adjuvant Everolimus Falls Short in High-Risk Renal Cancer
(MedPage Today) -- Adjuvant everolimus (Afinitor) failed to significantly improve recurrence-free survival (RFS) in patients with renal cell carcinoma (RCC) who were at high risk for recurrence after nephrectomy, according to results from a randomized... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 31, 2023 Category: Hematology Source Type: news
Drug Trials Snapshot: FOTIVDA
FOTIVDA is a prescription medicine used to treat adult patients with advance kidney cancer (advanced renal cell carcinoma or RCC) that has been treated with 2 or more prior medicines and has come back or did not respond to treatment. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 6, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
S2 Episode 4: Renal Cell Carcinoma and Quality-of-Life Research S2 Episode 4: Renal Cell Carcinoma and Quality-of-Life Research
Drs Sumanta Pal and Sarah P. Psutka discuss the current quality-of-life research in bladder cancer, prehabilitation practices, helpful technology, and how this can be applied to renal cell carcinoma.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2023 Category: Consumer Health News Tags: Urology InDiscussion Source Type: news
Highlights in Renal Cell Carcinoma From ASCO 2023 Highlights in Renal Cell Carcinoma From ASCO 2023
Data on combination therapies, real-world findings on TKIs, and 4-year follow-up of the CLEAR study are among the highlights in renal cell carcinoma from ASCO 2023, as reported by Dr Eric Jonasch.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
ASCO: Adding Atezolizumab to Cabozantinib No Benefit in Advanced Renal Cancer
FRIDAY, June 9, 2023 -- For patients with locally advanced or metastatic renal cell carcinoma with disease progression on or after immune checkpoint inhibitor treatment, the addition of atezolizumab to cabozantinib does not improve clinical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 9, 2023 Category: Pharmaceuticals Source Type: news
No Survival Benefit With Immune Checkpoint Inhibitor Rechallenge in Metastatic RCC
(MedPage Today) -- CHICAGO -- Adding atezolizumab (Tecentriq) to cabozantinib (Cabometyx) for patients with metastatic renal cell carcinoma (RCC) after progression on an immune checkpoint inhibitor failed to improve clinical outcomes and led... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2023 Category: Hematology Source Type: news
Cabozantinib Plus Nivolumab and Ipilimumab Increases PFS in Renal Cell Cancer
THURSDAY, May 11, 2023 -- Cabozantinib plus nivolumab and ipilimumab yields significantly longer progression-free survival than treatment with cabozantinib plus nivolumab alone among patients with previously untreated, advanced renal-cell carcinoma... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 11, 2023 Category: Pharmaceuticals Source Type: news
S2 Episode 2: How Single-Cell Sequencing Can Help in Renal Cell Carcinoma S2 Episode 2: How Single-Cell Sequencing Can Help in Renal Cell Carcinoma
Drs Sumanta Pal and David A. Braun discuss the role of single-cell sequencing as a biomarker in renal cell carcinoma, how it is evolving, and how it might apply in other domains.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 3, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
S2 Episode 1: Tissue Biomarkers and Renal Cell Carcinoma S2 Episode 1: Tissue Biomarkers and Renal Cell Carcinoma
Drs Sumanta Pal and Scott Haake discuss the biology of kidney cancer and how to incorporate tissue biomarkers into prospective studies on renal cell carcinoma.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 3, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
7 Myths About Kidney Cancer, Debunked
Kidney cancer may well be the least-known common cancer in the U.S. An estimated 81,800 new cases will be diagnosed this year, according to the American Cancer Society. In 2022, the disease was the eighth most common cancer, occurring more frequently than leukemia and thyroid cancer. Yet, when people are diagnosed, their reaction is often, “I didn’t even know you could get cancer of the kidneys,” says Dr. Alice C. Fan, an assistant professor of medicine in the division of oncology at Stanford University School of Medicine in Palo Alto, Calif.
Humans have two fist-sized kidneys (shaped like the eponymous b...
Source: TIME: Health - April 19, 2023 Category: Consumer Health News Authors: Katherine Hobson Tags: Uncategorized Cancer healthscienceclimate Source Type: news
CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer
(MedPage Today) -- ORLANDO -- An off-the-shelf, allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD70 demonstrated antitumor activity in patients with advanced clear cell renal cell carcinoma (RCC), according to results from... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 19, 2023 Category: Hematology Source Type: news
Post-Immunotherapy Combo Promising in Advanced RCC
(MedPage Today) -- Combination treatment with a hypoxia-inducible factor (HIF) 2α inhibitor and tyrosine kinase inhibitor induced responses in nearly a third of advanced renal cell carcinoma (RCC) patients previously treated with immunotherapy... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 3, 2023 Category: Hematology Source Type: news
Novel PET Imaging Agent Accurately IDs Clear Cell Renal Cancers
(MedPage Today) -- An investigational PET imaging agent -- zirconium-89 (89Zr)-deferoxamine (DFO)-girentuximab -- identified clear cell renal cell carcinoma (ccRCC) with high sensitivity and specificity, according to results from the phase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 13, 2023 Category: Hematology Source Type: news
Benefits Persist for Lenvatinib, Pembrolizumab in Renal Cell Cancer
MONDAY, March 13, 2023 -- For patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study published in the March issue of The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 13, 2023 Category: Pharmaceuticals Source Type: news
